{"pmid":32330477,"title":"Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain).","text":["Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain).","Gastroenterology","Rodriguez-Lago, Iago","Ramirez de la Piscina, Patricia","Elorza, Ainara","Merino, Olga","Ortiz de Zarate, Jone","Cabriada, Jose Luis","32330477"],"journal":"Gastroenterology","authors":["Rodriguez-Lago, Iago","Ramirez de la Piscina, Patricia","Elorza, Ainara","Merino, Olga","Ortiz de Zarate, Jone","Cabriada, Jose Luis"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330477","week":"202017|Apr 20 - Apr 26","doi":"10.1053/j.gastro.2020.04.043","keywords":["covid-19","inflammatory bowel disease","sars-cov-2","immunosuppression"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"locations":["Basque","Spain"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"_version_":1664996914954764288,"score":8.518259,"similar":[{"pmid":32305331,"pmcid":"PMC7161529","title":"Inflammatory bowel diseases and COVID-19: the invisible enemy.","text":["Inflammatory bowel diseases and COVID-19: the invisible enemy.","Gastroenterology","D'Amico, Ferdinando","Peyrin-Biroulet, Laurent","Danese, Silvio","32305331"],"journal":"Gastroenterology","authors":["D'Amico, Ferdinando","Peyrin-Biroulet, Laurent","Danese, Silvio"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305331","week":"202017|Apr 20 - Apr 26","doi":"10.1053/j.gastro.2020.04.032","keywords":["covid-19","coronavirus","inflammatory bowel disease","prevention"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664641855718948864,"score":67.03686},{"pmid":32211765,"title":"Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience.","text":["Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience.","The outbreak of the COVID-19 caused by Coronavirus SARS-CoV2, is rapidly spreading worldwide. This is the first pandemic caused by a Coronavirus in history. More than 150,000 confirmed cases worldwide are reported by the SARS-CoV2, with more than 5,000 COVID-19-related deaths on March 14th, 2020. Fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhoea, confusion, dyspnoea, and bilateral interstitial pneumonia are the common symptoms. No therapies are available, and the only way to contain the virus spread is to regularly and thoroughly clean oneself hands with an alcohol-based hand rub or wash them with soap and water, to maintain at least 1 metre (3 feet) distance from anyone who is coughing or sneezing, to avoid touching eyes, nose and mouth, and to stay home if one feels unwell. No data are available on the risk of COVID-19 and outcomes in inflammatory bowel disease (IBD) patients. Outbreak restrictions can impact on the IBD care. We aim to give a viewpoint on how operationally manage IBD patients ensuring quality of care in the current pandemic era.","J Crohns Colitis","Fiorino, Gionata","Allocca, Mariangela","Furfaro, Federica","Gilardi, Daniela","Zilli, Alessandra","Radice, Simona","Spinelli, Antonino","Danese, Silvio","32211765"],"abstract":["The outbreak of the COVID-19 caused by Coronavirus SARS-CoV2, is rapidly spreading worldwide. This is the first pandemic caused by a Coronavirus in history. More than 150,000 confirmed cases worldwide are reported by the SARS-CoV2, with more than 5,000 COVID-19-related deaths on March 14th, 2020. Fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhoea, confusion, dyspnoea, and bilateral interstitial pneumonia are the common symptoms. No therapies are available, and the only way to contain the virus spread is to regularly and thoroughly clean oneself hands with an alcohol-based hand rub or wash them with soap and water, to maintain at least 1 metre (3 feet) distance from anyone who is coughing or sneezing, to avoid touching eyes, nose and mouth, and to stay home if one feels unwell. No data are available on the risk of COVID-19 and outcomes in inflammatory bowel disease (IBD) patients. Outbreak restrictions can impact on the IBD care. We aim to give a viewpoint on how operationally manage IBD patients ensuring quality of care in the current pandemic era."],"journal":"J Crohns Colitis","authors":["Fiorino, Gionata","Allocca, Mariangela","Furfaro, Federica","Gilardi, Daniela","Zilli, Alessandra","Radice, Simona","Spinelli, Antonino","Danese, Silvio"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32211765","week":"202013|Mar 23 - Mar 29","doi":"10.1093/ecco-jcc/jjaa058","keywords":["covid-19","coronavirus","inflammatory bowel disease","pandemic","quality of care"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Humanitas","Milan"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["Water","Alcohols"],"_version_":1664638933347074048,"score":62.51861},{"pmid":32283100,"pmcid":"PMC7151253","title":"AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary.","text":["AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary.","DESCRIPTION: The purpose of this AGA Institute Clinical Practice Update is to rapidly review the emerging evidence and provide timely expert recommendations regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic. METHODS: This expert commentary was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely perspective on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology.","Gastroenterology","Rubin, David T","Feuerstein, Joseph D","Wang, Andrew Y","Cohen, Russell D","32283100"],"abstract":["DESCRIPTION: The purpose of this AGA Institute Clinical Practice Update is to rapidly review the emerging evidence and provide timely expert recommendations regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic. METHODS: This expert commentary was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely perspective on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology."],"journal":"Gastroenterology","authors":["Rubin, David T","Feuerstein, Joseph D","Wang, Andrew Y","Cohen, Russell D"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283100","week":"202016|Apr 13 - Apr 19","doi":"10.1053/j.gastro.2020.04.012","keywords":["coronavirus","crohn's disease","ibd","immunosuppression","sars-cov-2","ulcerative colitis"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664636704083935232,"score":55.55527},{"pmid":32335173,"title":"How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review.","text":["How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review.","OBJECTIVES: SARS-CoV-2 infection has now a global resonance. Data on how COVID-19 is affecting immunocompromised patients are however few. With our study we aimed to systematically review the current knowledge on SARS-CoV-2 cases in children and adults with immunosuppression, to evaluate outcomes in this special population. METHODS: A systematic review of literature was carried out to identify relevant articles, searching the EMBASE, Medline, and Google Scholar databases. Studies reporting data on pre-defined outcomes and related to immunosuppressed adults and children with SARS-CoV-2 were included. RESULTS: Sixteen relevant articles were identified with 110 immunosuppressed patients, mostly presenting cancer, along with transplantation and immunodeficiency. Cancer was more often associated with a more severe course, but not necessarily with a bad prognosis. Our data show that both children and adults with immunosuppression seem to have a favorable disease course, as compared to the general population. CONCLUSION: Immunosuppressed patients with COVID-19 seem to be few in relation to the overall figures, and to present a favorable outcome as compared to other comorbidities. This might be explained by a hypothetical protective role of a weaker immune response, determining a milder disease presentation and thus underdiagnosis. Nevertheless, surveillance on this special population should be encouraged.","J Infect","Minotti, Chiara","Tirelli, Francesca","Barbieri, Elisa","Giaquinto, Carlo","Dona, Daniele","32335173"],"abstract":["OBJECTIVES: SARS-CoV-2 infection has now a global resonance. Data on how COVID-19 is affecting immunocompromised patients are however few. With our study we aimed to systematically review the current knowledge on SARS-CoV-2 cases in children and adults with immunosuppression, to evaluate outcomes in this special population. METHODS: A systematic review of literature was carried out to identify relevant articles, searching the EMBASE, Medline, and Google Scholar databases. Studies reporting data on pre-defined outcomes and related to immunosuppressed adults and children with SARS-CoV-2 were included. RESULTS: Sixteen relevant articles were identified with 110 immunosuppressed patients, mostly presenting cancer, along with transplantation and immunodeficiency. Cancer was more often associated with a more severe course, but not necessarily with a bad prognosis. Our data show that both children and adults with immunosuppression seem to have a favorable disease course, as compared to the general population. CONCLUSION: Immunosuppressed patients with COVID-19 seem to be few in relation to the overall figures, and to present a favorable outcome as compared to other comorbidities. This might be explained by a hypothetical protective role of a weaker immune response, determining a milder disease presentation and thus underdiagnosis. Nevertheless, surveillance on this special population should be encouraged."],"journal":"J Infect","authors":["Minotti, Chiara","Tirelli, Francesca","Barbieri, Elisa","Giaquinto, Carlo","Dona, Daniele"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335173","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jinf.2020.04.026","keywords":["adults","cancer","children","immunosuppression","sars-cov-2","transplant"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1665172302009991168,"score":44.844234},{"pmid":32215548,"title":"Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","text":["Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?","Crohn's disease (CD)] and ulcerative colitis (UC), the main inflammatory bowel diseases (IBD) in human beings, are chronic, immune-inflammatory diseases, whose pathogenesis implicates a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant nowadays, as coronavirus disease (Covid-19) has rapidly spread from China to countries where IBD are more prevalent and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the cells and to illustrate the link between such determinants and the intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk to be infected with SARS-CoV-2 and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia.","J Crohns Colitis","Monteleone, Giovanni","Ardizzone, Sandro","32215548"],"abstract":["Crohn's disease (CD)] and ulcerative colitis (UC), the main inflammatory bowel diseases (IBD) in human beings, are chronic, immune-inflammatory diseases, whose pathogenesis implicates a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant nowadays, as coronavirus disease (Covid-19) has rapidly spread from China to countries where IBD are more prevalent and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the cells and to illustrate the link between such determinants and the intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk to be infected with SARS-CoV-2 and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia."],"journal":"J Crohns Colitis","authors":["Monteleone, Giovanni","Ardizzone, Sandro"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32215548","week":"202013|Mar 23 - Mar 29","doi":"10.1093/ecco-jcc/jjaa061","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664638838270590976,"score":42.076733}]}